Download PDF
Pneumologie 2017; 71(08): 543-548
DOI: 10.1055/s-0043-111909
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Nasal Nitric Oxide Measurement and a Modified PICADAR Score for the Screening of Primary Ciliary Dyskinesia in Adults with Bronchiectasis

Messung des nasalen Stickstoffmonoxids und ein modifizierter PICADAR-Score als Screening für primär ciliäre Dyskinesie in Erwachsenen mit Bronchiektasen
J. Rademacher
1   Department of Respiratory Medicine, Hannover Medical School
,
A. Buck
1   Department of Respiratory Medicine, Hannover Medical School
,
N. Schwerk
2   Clinic for Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School
,
M. Price
2   Clinic for Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School
,
J. Fuge
3   Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany
,
T. Welte
1   Department of Respiratory Medicine, Hannover Medical School
3   Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany
,
F. C. Ringshausen
1   Department of Respiratory Medicine, Hannover Medical School
3   Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany
› Author Affiliations
Further Information

Publication History

received28 March 2017

accepted after revision23 May 2017

Publication Date:
07 August 2017 (online)

Also available at
   Permissions and Reprints

Abstract

Background Determining the underlying diagnosis is essential for the targeted and specific treatment of bronchiectasis. Primary ciliary dyskinesia (PCD) is a rare genetic disease, which is characterized by abnormalities in ciliary structure and/or function and which may result in bronchiectasis. The disease is probably underestimated among adults with bronchiectasis due to the fact that extensive diagnostic testing is required and that the recognition of PCD is low.

Objective To evaluate a feasible screening algorithm for PCD among adults with bronchiectasis.

Methods Data from all patients who presented to our bronchiectasis outpatient clinic from June 2010 until July 2016 were retrospectively analysed from our database. Nasal NO (nNO) and a modified PICADAR score (PrImary CiliAry DyskinesiA Rule) were measured and compared in the two groups of PCD-bronchiectasis and non-PCD-bronchiectasis.

Results 185 of 365 patients (75 males, 110 females) had a sufficient measurement of nNO concentration and complete clinical data and were eligible for analysis. The mean (SD) nNO concentration in nL/ml was significant lower in the PCD group compared to the non-PCD group (25 [31] and 227 [112] nL/min, respectively; p < 0.001). A nNO level of 77 nL/min had the best discriminative value to differentiate between the two groups. Patients with PCD had a significant higher modified PIDACAR score than patients without PCD (5 [2] and 1 [1], respectively [p < 0.001]). Using ROC curve analysis, the modified PICADAR score of 2 had the best discriminative value with a sensitivity of 1.00 and a specificity of 0.89.

Conclusions Low nNO concentration and the modified PICADAR score are suitable and cheap screening tests for PCD in adults with bronchiectasis.

Zusammenfassung

Hintergrund Um Patienten mit Bronchiektasen gezielt und effektiv therapieren zu können, ist es notwendig die zugrunde liegende Ätiologie zu kennen. Die primär ciliäre Dyskinesie (PCD) ist eine seltene genetische Erkrankung mit Veränderungen in der Zilienstruktur und/oder -funktion, welche zu Bronchiektasen führen kann. Da die Diagnostik aufwendig, nur selten verfügbar und teuer ist, wird die PCD als Ätiologie für Bronchiektasen zum Teil erst spät erkannt und ist wahrscheinlich unterdiagnostiziert.

Zielsetzung Evaluierung eines einfachen Screeningverfahrens für PCD in Patienten mit Bronchiektasen.

Methoden Es wurden retrospektiv die Daten aller Patienten mit Bronchiektasen in der Spezialambulanz der Medizinischen Hochschule Hannover von Juni 2010 bis Juli 2016 analysiert. Das nasale NO (nNO) und der modifizierte PICADAR-Score (PrImary CiliAry DyskinesiA Rule) wurden gemessen und in den zwei Gruppen PCD-Bronchiektasen und Nicht-PCD-Bronchiektasen verglichen.

Ergebnisse 185 von 365 Patienten (75 Männer, 110 Frauen) hatten eine suffiziente nNO-Messung sowie vollständige klinische Daten und konnten in die Analyse eingeschlossen werden. Der Mittelwert (SD) der nNO-Konzentration in nL/ml war signifikant niedriger in der PCD-Gruppe im Vergleich zu Nicht-PCD-Patienten (25 [31] und 227 [112] nL/min; p < 0,001). Ein nNO von 77nL/min ist der beste diskrimitative Wert um zwischen diesen beiden Gruppen zu unterscheiden. Patienten mit PCD zeigten einen signifikant höheren PICADAR score als Patienten ohne PCD (5 [2] und 1 [1], (p < 0,001)). Der beste diskrimitative Wert des modifizierten PICADAR-Scores lag bei 2 mit einer Sensitivät von 1,00 und einer Spezifität von 0,89.

Schlussfolgerung Die Kombination aus niedrigem nNO und ein hoher modifizierter PICADAR-Score ist ein einfacher und kostengünstiger Screeningtest auf PCD bei Patienten mit Bronchiektasen.

 

  • References

  • 1 Barker AF. Bronchiectasis. N Engl J Med 2002; 346: 1383-1393
    CrossrefPubMedGoogle Scholar
  • 2 Lonni S, Chalmers JD, Goeminne PC. et al. Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. Ann Am Thorac Soc 2015; 12: 1764-1770
    CrossrefPubMedGoogle Scholar
  • 3 Quint JK, Millett ER, Joshi M. et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 2016; 47: 186-193
    CrossrefPubMedGoogle Scholar
  • 4 Ringshausen FC, de Roux A, Pletz MW. et al. Bronchiectasis-associated hospitalizations in Germany, 2005 – 2011: a population-based study of disease burden and trends. PLoS One 2013; 8: e71109
    CrossrefPubMedGoogle Scholar
  • 5 Ringshausen FC, de Roux A, Diel R. et al. Bronchiectasis in Germany: a population-based estimation of disease prevalence. Eur Respir J 2015; 46: 1805-1807
    CrossrefPubMedGoogle Scholar
  • 6 Wodehouse T, Kharitonov SA, Mackay IS. et al. Nasal nitric oxide measurements for the screening of primary ciliary dyskinesia. Eur Respir J 2003; 21: 43-47
    CrossrefPubMedGoogle Scholar
  • 7 Altenburg J, Wortel K, van der Werf TS. et al. Non-cystic fibrosis bronchiectasis: clinical presentation, diagnosis and treatment, illustrated by data from a Dutch Teaching Hospital. Neth J Med 2015; 73: 147-154
    PubMedGoogle Scholar
  • 8 Coren ME, Meeks M, Morrison I. et al. Primary ciliary dyskinesia: age at diagnosis and symptom history. Acta Paediatr 2002; 91: 667-669
    CrossrefPubMedGoogle Scholar
  • 9 Kuehni CE, Frischer T, Strippoli MP. et al. ERS Task Force on Primary Ciliary Dyskinesia in Children. Factors influencing age at diagnosis of primary ciliary dyskinesia in European children. Eur Respir J 2010; 36: 1248-1258
    CrossrefPubMedGoogle Scholar
  • 10 Lundberg JO, Weitzberg E, Nordvall SL. et al. Primarily nasal origin of exhaled nitric oxide and absence in Kartagener's syndrome. Eur Respir J 1994; 7: 1501-1504
    CrossrefPubMedGoogle Scholar
  • 11 Bush A, Chodhari R, Collins N. et al. Primary ciliary dyskinesia: current state of the art. Arch Dis Child 2007; 92: 1136-1140
    CrossrefPubMedGoogle Scholar
  • 12 Karadag B, James AJ, Gültekin E. et al. Nasal and lower airway level of nitric oxide in children with primary ciliary dyskinesia. Eur Respir J 1999; 13: 1402-1405
    CrossrefPubMedGoogle Scholar
  • 13 Narang I, Ersu R, Wilson NM. et al. Nitric oxide in chronic airway inflammation in children: diagnostic use and pathophysiological significance. Thorax 2002; 57: 586-589
    CrossrefPubMedGoogle Scholar
  • 14 Walker WT, Jackson CL, Lackie PM. et al. Nitric oxide primary ciliary dyskinesia. Eur Respir J 2012; 40: 1024-1032
    CrossrefPubMedGoogle Scholar
  • 15 Shah A, Shoemark A, MacNeill SJ. et al. A longitudinal study characterising a large adult primary ciliary dyskinesia population. Eur Respir J 2016; 48: 441-450
    CrossrefPubMedGoogle Scholar
  • 16 Noone PG, Leigh MW, Sannuti A. et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004; 169: 459-467
    CrossrefPubMedGoogle Scholar
  • 17 Behan L, Dimitrov BD, Kuehni CE. et al. PICADAR: a diagnostic predictive tool for primary ciliary dyskinesia. Eur Respir J 2016; 47: 1103-1112
    CrossrefPubMedGoogle Scholar
  • 18 McShane PJ, Naureckas ET, Tino G. et al. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013; 188: 647-656
    CrossrefPubMedGoogle Scholar
  • 19 Pasteur MC, Bilton D, Hill AT. British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65: 577
    CrossrefPubMedGoogle Scholar
  • 20 Werner C, Lablans M, Ataian M. et al. An international registry for primary ciliary dyskinesia. Eur Respir J 2016; 47: 849-859
    CrossrefPubMedGoogle Scholar
  • 21 American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med 2005; 171: 912-930
    CrossrefPubMedGoogle Scholar
  • 22 Collins SA, Gove K, Walker W. et al. Nasal nitric oxide screening for primary ciliary dyskinesia: systematic review and meta-analysis. Eur Respir J 2014; 44: 1589-1599
    CrossrefPubMedGoogle Scholar
  • 23 Shoemark A, Wilson R. Bronchial and peripheral airway nitric oxide in primary ciliary dyskinesia and bronchiectasis. Respir Med 2009; 103: 700-706
    CrossrefPubMedGoogle Scholar
  • 24 Horváth I, Loukides S, Wodehouse T. et al. Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia. Thorax 2003; 58: 68-72
    CrossrefPubMedGoogle Scholar
  • 25 Mahut B, Escudier E, de Blic J. et al. Impairment of nitric oxide output of conducting airways in primary ciliary dyskinesia. Pediatr Pulmonol 2006; 41: 158-163
    CrossrefPubMedGoogle Scholar
  • 26 Jackson CL, Behan L, Collins SA. et al. Accuracy of diagnostic testing in primary ciliary dyskinesia. Eur Respir J 2016; 47: 837-848
    CrossrefPubMedGoogle Scholar
  • 27 Nüsslein T, Brinkmann F, Ahrens P. et al. Diagnostik der primären ziliären Dykinesie. Monatsschr Kinderheilkd 2013; 161: 406-416
    CrossrefPubMedGoogle Scholar